Every 10-Q that Cycurion, Inc. (CYCU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CYCU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYCU filings page.
Cycurion, Inc. reported continued losses and liquidity pressure for the six months ended June 30, 2026 while expanding via acquisitions. Revenue was $7,025,696, slightly below the prior-year period, but gross profit improved to $1,781,695 as cost of revenue declined. Net loss attributable to Cycurion narrowed to $5,884,236 from a much larger loss in 2025, primarily because prior-year business combination expenses of over $11 million did not recur.
Cash and cash equivalents fell to $1,873,287 from $5,255,235 at year-end, driven by $6,174,176 of operating cash outflows. The company disclosed a $13.6 million working capital deficit and an accumulated deficit of $32.8 million, and stated there is substantial doubt about its ability to continue as a going concern absent improved cash flow and new capital.
Cycurion completed the acquisition of Secuvant, LLC on June 3, 2026 for total consideration of $5,436,837, recording preliminary goodwill and intangibles that helped lift total goodwill and intangibles to $27,617,398. Debt remains significant, including a $2,421,305 revolving credit balance, $2,686,748 of 12% convertible notes, and $1,161,960 of promissory notes. The company also detailed Nasdaq listing challenges; after an October 2025 reverse stock split, it again fell below the $1.00 bid-price requirement in July 2026 and has requested a Nasdaq hearing scheduled for August 20, 2026.
Cycurion, Inc. reports first-quarter 2026 results showing continued losses and liquidity pressure while highlighting prior Nasdaq listing remediation and capital structure changes. Revenue for the three months ended March 31, 2026 was $3.27 million, down from $3.87 million a year earlier, with gross profit of $0.69 million. Net loss attributable to Cycurion narrowed to $2.13 million from $10.25 million, but the company used $2.89 million of cash in operating activities and ended the quarter with cash of $2.03 million.
Management discloses substantial doubt about Cycurion’s ability to continue as a going concern, citing an accumulated deficit of $29.0 million and a working capital deficit of $12.0 million as of March 31, 2026. The company plans to improve operations and pursue a public offering of common stock to raise capital and facilitate conversion of debt and preferred stock. The filing also describes a reverse recapitalization via a 2025 SPAC business combination, consolidation of SLG as a variable interest entity, a one-for-thirty reverse stock split in October 2025, and actions taken in 2025 to regain compliance with Nasdaq Global Market listing rules.
Cycurion (CYCU) filed its Q3 2025 10‑Q, reporting quarterly net revenues of $3,833,038 and a net loss attributable to Cycurion of $3,123,317. For the nine months, revenue reached $11,591,003 with a net loss of $18,560,558, driven by higher operating expenses and business combination costs.
The company disclosed substantial doubt about its ability to continue as a going concern, citing an accumulated deficit of $21.8M, a working capital deficit of $9.6M, and operating cash outflow of $8.77M for the nine months, all as of September 30, 2025. Cash and cash equivalents were $3,652,074 at period end.
Cycurion completed a reverse recapitalization with Western Acquisition Ventures in February 2025 and consolidated SLG Innovation under a Management Services Agreement, recording goodwill. The company executed a 1‑for‑30 reverse stock split effective October 27, 2025 and subsequently announced that it regained compliance with Nasdaq’s Bid Price Rule, avoiding delisting. Common shares outstanding were 2,712,489 as of November 7, 2025.